OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
1. OSTX granted FDA End of Phase 2 Meeting for OST-HER2 program. 2. Rolling Review may expedite the Biologics Licensing Application submission. 3. OST-HER2 received Orphan Disease and Fast Track designations from the FDA. 4. Priority Review Voucher could generate significant revenue if accelerated approval is received. 5. OS Therapies advancing canine osteosarcoma treatment through OS Animal Health.